Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of October 2016
Date of Filing: October 25, 2016
The filing reports a strategic partnership announcement regarding the company's lead product candidate, CF102.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate development event.
Transaction Value: The announced distribution agreement includes potential payments of up to $3,000,000 in upfront and milestone payments, plus royalties on net sales in the low twenties.
Material Changes
- New Distribution Agreement: Signed with Chong Kun Dang Pharmaceuticals.
- Scope: Exclusive rights to distribute CF102 for the treatment of liver cancer in South Korea.
- Condition: Rights are effective upon receipt of regulatory approvals.
Outlook and Management Commentary
Management highlighted the expansion of commercial reach for CF102 into the South Korean market. The agreement structure relies on regulatory milestones and future sales performance rather than immediate cash inflow, as the upfront and milestone payments are contingent upon regulatory approvals.
Investor Verification Checklist
- Verify the status of regulatory approvals for CF102 in South Korea required to trigger payments.
- Confirm the specific royalty percentage within the "low twenties" range.
- Review the full text of the distribution agreement (Exhibit 99.1) for specific milestone definitions.
- Assess the financial impact of the $3,000,000 potential payments relative to the company's current cash position (not provided in this filing).